Pharmacology researchers develop a novel immunotherapy to treat malignancies. In this therapy, T lymphocytes are harvested from patients with a malignancy and genetically modified to express a chimeric antigen receptor composed of an extracellular antigen recognition domain linked with an intracellular T-cell signaling domain. These modified T cells are expanded ex vivo and then infused back into the patient, where they destroy the cancer cells. In one of the experiments, they modify the chimeric antigen receptor to recognize CD19. Use of this treatment is most likely to have which of the following potential complications?

Question

Pharmacology researchers develop a novel immunotherapy to treat malignancies.  In this therapy, T lymphocytes are harvested from patients with a malignancy and genetically modified to express a chimeric antigen receptor composed of an extracellular antigen recognition domain linked with an intracellular T-cell signaling domain.  These modified T cells are expanded ex vivo and then infused back into the patient, where they destroy the cancer cells.  In one of the experiments, they modify the chimeric antigen receptor to recognize CD19.  Use of this treatment is most likely to have which of the following potential complications?

Quizplus · Accepted Answer

Eductional Objective: Chimeric antigen receptor (CAR) T-cell therapy involves extracting T cells from a patient with malignancy, inserting a CAR gene against a protein overexpressed by the malignancy, and then reinfusing the modified T cells back into the patient.  CAR T-cell therapy against CD19 is used to treat B-cell malignancy because CD19 is expressed only by B cells.

Pharmacology Researchers Develop a Novel Immunotherapy to Treat Malignancies